Takashi Matsuyama
Overview
Explore the profile of Takashi Matsuyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
855
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ohashi N, Takase H, Aoki T, Matsuyama T, Ishigaki S, Isobe S, et al.
Medicine (Baltimore)
. 2021 Jun;
100(19):e25931.
PMID: 34106662
Excessive salt intake causes hypertension and cardiovascular diseases (CVDs). B-type natriuretic peptide (BNP) is synthesized and released from the ventricle, and is a surrogate marker reflecting various CVDs. Moreover, when...
12.
Ishigaki S, Ohashi N, Aoki T, Matsuyama T, Isobe S, Sato T, et al.
Intern Med
. 2021 Feb;
60(14):2201-2206.
PMID: 33612680
Objective The intrarenal renin-angiotensin system (RAS) is activated in patients with chronic kidney disease (CKD), and urinary angiotensinogen (AGT) levels, a surrogate marker of the intrarenal RAS activation, are associated...
13.
Matsuyama T, Ohashi N, Aoki T, Ishigaki S, Isobe S, Sato T, et al.
Hypertens Res
. 2021 Feb;
44(6):618-627.
PMID: 33558668
Circadian fluctuation disorder of the intrarenal renin-angiotensin system (RAS) causes that of blood pressure (BP) and renal damage. In renal damage with an impaired glomerular filtration barrier, liver-derived angiotensinogen (AGT)...
14.
Morita A, Takahashi H, Ozawa K, Imafuku S, Takekuni N, Takahashi K, et al.
J Dermatol
. 2020 Oct;
48(1):3-13.
PMID: 33029861
This phase 3, multicenter, open-label single-arm study evaluated adalimumab (ADA) in Japanese patients with moderate to severe hidradenitis suppurativa (HS). Fifteen patients received ADA 160 mg s.c. at week 0,...
15.
Ohashi N, Aoki T, Matsuyama T, Ishigaki S, Isobe S, Fujikura T, et al.
Med Sci Monit
. 2020 Oct;
26:e926086.
PMID: 33004785
BACKGROUND Sodium-glucose cotransporter-2 (SGLT2) inhibitors are new antihyperglycemic drugs for type 2 diabetes. SGLT2 inhibitors ameliorate cardiovascular morbidity and mortality as well as kidney disease progression by reducing body weight...
16.
Aoki T, Ohashi N, Isobe S, Ishigaki S, Matsuyama T, Sato T, et al.
Intern Med
. 2020 Sep;
59(18):2237-2244.
PMID: 32938851
Objective The intrarenal renin-angiotensin system (RAS) is activated in chronic kidney disease (CKD) patients and is not suppressed at night in CKD patients showing nocturnal hypertension, contributing to renal damage....
17.
Tsuji T, Ohashi N, Sato T, Goto D, Nagata S, Matsuyama T, et al.
Clin Nephrol
. 2019 Dec;
93(3):152-157.
PMID: 31854296
Introduction: Patients without detectable serum antiglomerular basement membrane (GBM) antibodies but with GBM staining for immunoglobulins (Ig), absence of a crescentic phenotype, mild renal insufficiency, and absence of pulmonary hemorrhage...
18.
Ohashi N, Aoki T, Matsuyama T, Ishigaki S, Isobe S, Katahashi N, et al.
Intern Med
. 2019 Sep;
59(3):357-364.
PMID: 31534091
Objective Urinary angiotensinogen (AGT) is a surrogate marker for intrarenal renin-angiotensin system (RAS) activity that plays an important role in the development of renal damage. Urinary AGT levels are determined...
19.
Ikegawa Y, Honma A, Himuro C, Matsuyama T
J Econ Entomol
. 2019 Sep;
112(6):2976-2983.
PMID: 31504650
Quarantine pests in plants can be a serious agricultural problem; many eradication programs using area-wide control measures have been implemented worldwide to combat this threat. Surveillance measures using sex pheromone...
20.
Matsuyama T
J Biosci Bioeng
. 2019 Jul;
128(6):655-661.
PMID: 31324384
Metabolically engineered microorganisms that produce useful organic compounds will be helpful for realizing a sustainable society. The budding yeast Saccharomyces cerevisiae has high utility as a metabolic engineering platform because...